USD 0.35
(2.88%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 62.83 Million USD | -15.5% |
2022 | 74.36 Million USD | 1.25% |
2021 | 73.44 Million USD | 4.39% |
2020 | 70.35 Million USD | 12.58% |
2019 | 62.49 Million USD | 18.08% |
2018 | 52.92 Million USD | -1.12% |
2017 | 53.52 Million USD | 6.55% |
2016 | 50.23 Million USD | 25.55% |
2015 | 40 Million USD | 54.95% |
2014 | 25.82 Million USD | -78.74% |
2013 | 121.42 Million USD | 63.89% |
2012 | 74.08 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 27.61 Million USD | -55.83% |
2024 Q1 | 62.52 Million USD | -0.49% |
2023 Q4 | 62.83 Million USD | 0.51% |
2023 Q3 | 62.51 Million USD | -15.0% |
2023 Q1 | 82.61 Million USD | 11.11% |
2023 Q2 | 73.55 Million USD | -10.97% |
2023 FY | 62.83 Million USD | -15.5% |
2022 Q2 | 77.12 Million USD | 3.26% |
2022 Q3 | 75.62 Million USD | -1.95% |
2022 Q4 | 74.36 Million USD | -1.67% |
2022 FY | 74.36 Million USD | 1.25% |
2022 Q1 | 74.69 Million USD | 1.7% |
2021 Q1 | 70.61 Million USD | 0.38% |
2021 Q3 | 72.5 Million USD | 3.74% |
2021 Q4 | 73.44 Million USD | 1.3% |
2021 Q2 | 69.88 Million USD | -1.03% |
2021 FY | 73.44 Million USD | 4.39% |
2020 Q3 | 60.05 Million USD | 3.36% |
2020 Q4 | 70.35 Million USD | 17.14% |
2020 FY | 70.35 Million USD | 12.58% |
2020 Q1 | 59.04 Million USD | -5.51% |
2020 Q2 | 58.1 Million USD | -1.6% |
2019 Q1 | 57.13 Million USD | 7.96% |
2019 FY | 62.49 Million USD | 18.08% |
2019 Q3 | 60.16 Million USD | -1.03% |
2019 Q2 | 60.79 Million USD | 6.4% |
2019 Q4 | 62.49 Million USD | 3.87% |
2018 Q1 | 52.2 Million USD | -2.46% |
2018 Q2 | 52.23 Million USD | 0.05% |
2018 Q3 | 52.13 Million USD | -0.19% |
2018 Q4 | 52.92 Million USD | 1.51% |
2018 FY | 52.92 Million USD | -1.12% |
2017 Q3 | 51.55 Million USD | 0.19% |
2017 FY | 53.52 Million USD | 6.55% |
2017 Q4 | 53.52 Million USD | 3.82% |
2017 Q2 | 51.45 Million USD | 3.67% |
2017 Q1 | 49.62 Million USD | -1.2% |
2016 Q2 | 43.25 Million USD | 8.54% |
2016 Q3 | 41.42 Million USD | -4.23% |
2016 Q4 | 50.23 Million USD | 21.27% |
2016 FY | 50.23 Million USD | 25.55% |
2016 Q1 | 39.84 Million USD | -0.4% |
2015 Q2 | 29.66 Million USD | 1.25% |
2015 Q1 | 29.29 Million USD | 13.45% |
2015 Q3 | 29.31 Million USD | -1.17% |
2015 Q4 | 40 Million USD | 36.48% |
2015 FY | 40 Million USD | 54.95% |
2014 Q4 | 25.82 Million USD | 48.08% |
2014 Q3 | 17.43 Million USD | -86.27% |
2014 Q2 | 127.03 Million USD | 761.11% |
2014 FY | 25.82 Million USD | -78.74% |
2014 Q1 | 14.75 Million USD | -87.85% |
2013 Q4 | 121.42 Million USD | 0.0% |
2013 FY | 121.42 Million USD | 63.89% |
2013 Q1 | - USD | 0.0% |
2012 FY | 74.08 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Bionano Genomics, Inc. | 118.24 Million USD | 46.863% |
Prenetics Global Limited | 44.01 Million USD | -42.759% |
Star Equity Holdings, Inc. | 21.67 Million USD | -189.887% |
CareDx, Inc | 223.28 Million USD | 71.86% |
Exact Sciences Corporation | 3.32 Billion USD | 98.111% |
Exagen Inc. | 34.25 Million USD | -83.454% |
Inotiv, Inc. | 588.04 Million USD | 89.315% |
Guardant Health, Inc. | 1.62 Billion USD | 96.14% |
Biodesix, Inc. | 94.51 Million USD | 33.521% |
BioNexus Gene Lab Corp. | 1.74 Million USD | -3507.068% |
Precipio, Inc. | 3.67 Million USD | -1611.138% |
iSpecimen Inc. | 6.07 Million USD | -933.767% |
Natera, Inc. | 691.79 Million USD | 90.917% |
Aspira Women's Health Inc. | 8.62 Million USD | -628.33% |
Standard BioTools Inc. | 159.86 Million USD | 60.696% |
23andMe Holding Co. | 206.64 Million USD | 69.594% |
Castle Biosciences, Inc. | 86.54 Million USD | 27.396% |
Personalis, Inc. | 95.65 Million USD | 34.315% |
Aclaris Therapeutics, Inc. | 40.22 Million USD | -56.2% |
Applied DNA Sciences, Inc. | 8.77 Million USD | -615.706% |
OpGen, Inc. | 13.44 Million USD | -367.373% |
Myriad Genetics, Inc. | 312.9 Million USD | 79.919% |
ICON Public Limited Company | 7.74 Billion USD | 99.189% |
NeoGenomics, Inc. | 739.69 Million USD | 91.506% |
Star Equity Holdings, Inc. | 21.67 Million USD | -189.887% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 96.461% |
RadNet, Inc. | 2.07 Billion USD | 96.969% |
MDxHealth SA | 121.92 Million USD | 48.465% |
Psychemedics Corporation | 6.59 Million USD | -852.304% |
Illumina, Inc. | 4.36 Billion USD | 98.561% |
Check-Cap Ltd. | 1.33 Million USD | -4624.286% |
Twist Bioscience Corporation | 152.97 Million USD | 58.925% |
DarioHealth Corp. | 38.24 Million USD | -64.291% |
Fulgent Genetics, Inc. | 139.82 Million USD | 55.062% |
Sera Prognostics, Inc. | 25.28 Million USD | -148.519% |
ENDRA Life Sciences Inc. | 1.09 Million USD | -5637.351% |
OPKO Health, Inc. | 622.47 Million USD | 89.906% |
Medpace Holdings, Inc. | 1.09 Billion USD | 94.277% |
Neogen Corporation | 1.44 Billion USD | 95.637% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | -1022.886% |
Prenetics Global Limited | 44.01 Million USD | -42.759% |
Mainz Biomed B.V. | 12.15 Million USD | -416.727% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -1766.532% |
Trinity Biotech plc | 83.38 Million USD | 24.646% |
Neuronetics, Inc. | 81.64 Million USD | 23.037% |
Sotera Health Company | 2.68 Billion USD | 97.661% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -1766.532% |